Exploring the Role of iPSC-Cardiomyocytes in Drug Discovery and Safety Assessment

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly utilized in basic biology research, drug discovery applications, and for studies of disease mechanisms. The opportunity to measure the contractility, viability, and electrophysiology of hiPSC-CMs in real time over extended periods can provide researchers unique mechanistic insights into the roles cardiomyocytes play in both normal development and cardiac disease.

In this special webinar, scientists using hiPSC-CMs will describe new approaches aimed at enhancing assessment of hiPSC-CM functionality. The speakers will also discuss how these approaches can be used to explore compounds that modulate the force of cardiomyocyte contraction or to assess the safety and efficacy of drugs and drug combinations targeting cardiac tissue.

In this webinar, you will gain insights on:

  • New instrumentation to assess cardiomyocyte contractility, viability, and electrophysiology
  • Label-free, real-time techniques to assess the “beating” of cardiomyocytes as a biologically-relevant measure of cardiomyocyte function
  • Use of electrical pacing for further maturation of cardiomyocytes
  • Techniques to detect functional cardiotoxicity

In addition, you will also be able to ask your own specific questions of the speakers during a live question-and-answer session following the presentations.

Learn More about the xCELLigence CardioECR       Click here
Featured Speaker:

Armando Lagrutta, PhD
Merck & Co. Inc.
Kristina Green, PhD
MyoKardia, Inc.


Patrick C.H. Lo, PhD
Senior Editor,